Subtype
Lung Small Cell Carcinoma
CI-CAN-00005832SCLCExplore in graph →
381 active trials6 approved drugs6 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005832SCLCExplore in graph →
Clinical trials
1,100 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (157)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04056247 | Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments(PROPHETIC) | active not recruiting | — | 10,000 | OncoHost Ltd.INDUSTRY | 5 | Oct 15, 2025 | clinicaltrials |
| NCT07206563 | Penfluridol for Relapsed/Refractory Small Cell Cancers | not yet recruiting | Phase 1 / Phase 2 | 33 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER |
| 1 |
| Oct 3, 2025 |
| clinicaltrials |
| NCT04472949 | Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). | active not recruiting | Phase 2 | 46 | Swiss Cancer InstituteOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT04986670 | NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer | active not recruiting | N/A | 299 | Tufts UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07200154 | Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC | not yet recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT06838208 | Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC | recruiting | Phase 2 | 56 | Anhui Provincial Cancer HospitalOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT06805825 | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | recruiting | Phase 1 | 67 | Novelty Nobility, Inc.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | active not recruiting | Phase 2 | 1,609 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2025 | clinicaltrials |
| NCT06505824 | A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06021483 | Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection | recruiting | — | 300 | Boryung Pharmaceutical Co., LtdINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07173244 | A Real-world Study of Adebrelimab-based Combination Regimens in the Treatment of Advanced Solid Tumors | not yet recruiting | — | 300 | Tianjin First Central HospitalOTHER | 0 | Sep 15, 2025 | clinicaltrials |
| NCT07173946 | Prospective Observational Study on ES-SCLC | not yet recruiting | — | 96 | Peking Union Medical College HospitalOTHER | 0 | Sep 15, 2025 | clinicaltrials |
| NCT07145333 | Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms(Drug-SNP) | active not recruiting | Phase 2 / Phase 3 | 600 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairINDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT05874401 | Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan | recruiting | Phase 4 | 302 | Pharmacosmos A/SINDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06529081 | Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung Cancer | recruiting | N/A | 165 | Copernicus Memorial HospitalOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT05796089 | Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy(CHEST RT) | active not recruiting | Phase 2 | 35 | Trans Tasman Radiation Oncology GroupOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT07141771 | An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing | not yet recruiting | Phase 1 / Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT06258642 | Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC | recruiting | N/A | 39 | Fudan UniversityOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT07109401 | Perioperative Immunotherapy for Resectable Limited-Stage SCLC | recruiting | Phase 2 | 37 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07110363 | A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer | not yet recruiting | Phase 1 | 58 | Biotroy TherapeuticsINDUSTRY | 0 | Aug 7, 2025 | clinicaltrials |
| NCT06592638 | A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer | recruiting | Phase 1 | 30 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07106528 | Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 128 | Peking Union Medical College HospitalOTHER | 0 | Aug 6, 2025 | clinicaltrials |
| NCT07103408 | A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 56 | Sun Yat-sen UniversityOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT07097948 | Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033(Adjuvant) | not yet recruiting | Phase 2 | 40 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07076914 | Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy(PPI-PROTECT) | not yet recruiting | Phase 2 | 58 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07076095 | A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer | not yet recruiting | Phase 2 | 200 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 0 | Jul 21, 2025 | clinicaltrials |
| NCT03670056 | Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy | active not recruiting | Phase 2 | 25 | Yale UniversityOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT07070011 | Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer | recruiting | — | 38 | Shanghai Chest Hospital of Shanghai Jiao Tong UniversityOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06457906 | SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC(SHARP) | recruiting | Phase 3 | 340 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07069270 | A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy | not yet recruiting | Phase 2 | 28 | Fujian Cancer HospitalOTHER_GOV | 0 | Jul 16, 2025 | clinicaltrials |
| NCT07063407 | Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer | not yet recruiting | Phase 1 | 50 | Shanghai Hansoh Biomedical Co., LtdINDUSTRY | 0 | Jul 14, 2025 | clinicaltrials |
| NCT05224141 | Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) | active not recruiting | Phase 3 | 460 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Jul 8, 2025 | clinicaltrials |
| NCT05557708 | A Safety Study of 212Pb-Pentixather Radioligand Therapy | not yet recruiting | Early Phase 1 | 20 | Yusuf MendaOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT05623319 | Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)(THOR) | recruiting | Phase 2 | 60 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06954246 | A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | recruiting | Phase 3 | 450 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 18, 2025 | clinicaltrials |
| NCT07026669 | A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer | recruiting | — | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT04952480 | Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer(DARTS) | recruiting | Phase 2 | 31 | AHS Cancer Control AlbertaOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT07004712 | Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer | not yet recruiting | Phase 2 | 46 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT02041845 | Two Schedules of Hyperfractionated Thoracic Radiotherapy in Limited Disease Small Cell Lung Cancer(THORA) | active not recruiting | N/A | 177 | Norwegian University of Science and TechnologyOTHER | 3 | Jun 6, 2025 | clinicaltrials |
| NCT07008716 | Omitting CTV for Primary Tumor in LS-SCLC | recruiting | Phase 3 | 852 | Sun Yat-sen UniversityOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06902350 | Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors | recruiting | Phase 1 | 102 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT06419179 | Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)(GUIDANCE) | enrolling by invitation | Phase 2 | 29 | University of CologneOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT06978153 | This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 66 | Tang-Du HospitalOTHER | 0 | May 18, 2025 | clinicaltrials |
| NCT06970795 | A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 180 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT06961201 | Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase | not yet recruiting | Phase 3 | 94 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 7, 2025 | clinicaltrials |
| NCT06951841 | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction | not yet recruiting | Phase 4 | 31 | China Medical University, ChinaOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06914050 | Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Apr 25, 2025 | clinicaltrials |
| NCT06931145 | Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer | not yet recruiting | Phase 4 | 50 | Peking Union Medical College HospitalOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT04706962 | TH1902 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 70 | TheratechnologiesINDUSTRY | 2 | Apr 15, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Oct 15, 2025source: clinicaltrials